How to appeal a Highmark pediatric oncology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for pediatric oncology

Cited policy: BCBS Tumor-Agnostic Targeted Therapy (Vitrakvi / Rozlytrek / Koselugo / Ojemda)

Documented molecular biomarker (NTRK fusion / NF1 mutation / BRAF V600E / BRAF fusion). Age-appropriate per FDA label. Prescribed by/in consultation with pediatric oncologist.

How Highmark denies pediatric oncology — and how to counter it

Where Highmark pushes back: 1) Off-label use; 2) Not on formulary; 3) Try chemo first.

Counter-arguments that hold up: Vitrakvi (larotrectinib) tumor-agnostic FDA approval Nov 26, 2018 — by definition NOT off-label when NTRK fusion documented. Drilon NEJM 2018 + Laetsch Lancet Oncol 2018 pediatric SCOUT. Koselugo (selumetinib) FDA Apr 10, 2020 NF1 plexiform neurofibromas (SPRINT NEJM 2020). Ojemda (tovorafenib) FDA Apr 23, 2024 pediatric LGG. Submit NGS report + matched FDA label.

What Highmark typically denies for pediatric oncology

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric oncology, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the pediatric oncology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• COG trial enrollment
• CAR-T (Kymriah)
• Proton therapy
• Pediatric immunotherapy
• Targeted therapy
• ALL chemo regimen

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.